Segments (Tables)

9 Months Ended

Sep. 30, 2021

Segment Adjusted EBITDA by reportable segment was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Biopharmaceuticals	$	(12,661)	$	(8,761)	$	(34,055)	$	(26,106)
Exemplar	1,617		1,654		5,312		2,511
Trans Ova	(2,552)		(251)		15,881		7,417
Segment Adjusted EBITDA for reportable segments	$	(13,596)	$	(7,358)	$	(12,862)	$	(16,178)

Revenues by reportable segment were as follows:


	Three Months Ended September 30, 2021
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	129	$	3,204	$	18,228	$	21,561
Intersegment revenues	1,141		—		126		1,267
Total segment revenues	$	1,270	$	3,204	$	18,354	$	22,828


	Three Months Ended September 30, 2020
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	5,381	$	2,974	$	15,228	$	23,583
Intersegment revenues	1,919		—		55		1,974
Total segment revenues	$	7,300	$	2,974	$	15,283	$	25,557


	Nine Months Ended September 30, 2021
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	723	$	9,860	$	69,069	$	79,652
Intersegment revenues	1,469		—		324		1,793
Total segment revenues	$	2,192	$	9,860	$	69,393	$	81,445


	Nine Months Ended September 30, 2020
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	20,703	$	7,230	$	55,858	$	83,791
Intersegment revenues	5,521		—		254		5,775
Total segment revenues	$	26,224	$	7,230	$	56,112	$	89,566

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Segment Adjusted EBITDA for reportable segments	$	(13,596)	$	(7,358)	$	(12,862)	$	(16,178)

Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,962		244		3,360		3,395
Add recognition of previously deferred revenue associated with upfront and milestone payments	1,163		7,132		1,849		25,178
Other expenses:
Interest expense	(4,799)		(4,646)		(14,005)		(13,830)
Depreciation and amortization	(3,399)		(3,786)		(10,442)		(11,364)
Loss on disposals of assets	(318)		(615)		(553)		(1,593)
Impairment losses	—		(920)		(543)		(920)

Stock-based compensation expense	(2,490)		(4,628)		(11,462)		(15,249)
Adjustment related to accrued bonuses paid in equity awards	—		—		—		2,833
Equity in net loss of affiliates	—		(523)		(3)		(1,125)
Other	(5)		4		(19)		16
Unallocated corporate costs	(7,166)		(10,452)		(25,412)		(29,102)
Eliminations	(1,237)		(2,038)		(1,812)		(6,282)
Consolidated net loss from continuing operations before income taxes	$	(29,885)	$	(27,586)	$	(71,904)	$	(64,221)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Total segment revenues from reportable segments	$	22,828	$	25,557	$	81,445	$	89,566
Other revenues	—		—		—		54
Elimination of intersegment revenues	(1,267)		(1,974)		(1,793)		(5,775)
Total consolidated revenues	$	21,561	$	23,583	$	79,652	$	83,845